Genetic Mapping of APP and Amyloid-β Biology Modulation by Trisomy 21.

Autor: Mumford P; The UK Dementia Research Institute, University College London, London, WC1N 3BG, United Kingdom., Tosh J; Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, WC1N 3BG, United Kingdom., Anderle S; The UK Dementia Research Institute, University College London, London, WC1N 3BG, United Kingdom., Gkanatsiou Wikberg E; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg S-431 80, Sweden., Lau G; The UK Dementia Research Institute, University College London, London, WC1N 3BG, United Kingdom., Noy S; Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, WC1N 3BG, United Kingdom., Cleverley K; Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, WC1N 3BG, United Kingdom., Saito T; Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, Saitama Japan, 351-0198., Saido TC; Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, Saitama Japan, 351-0198., Yu E; Genetics and Genomics Program and Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Children's Guild Foundation Down Syndrome Research Program, Buffalo, New York NY 14263., Brinkmalm G; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg S-431 80, Sweden., Portelius E; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg S-431 80, Sweden., Blennow K; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg S-431 80, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal S-43180, Sweden., Zetterberg H; The UK Dementia Research Institute, University College London, London, WC1N 3BG, United Kingdom.; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg S-431 80, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal S-43180, Sweden.; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, WC1N 3BG, United Kingdom.; Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China., Tybulewicz V; The Francis Crick Institute, London, NW1 1AT, United Kingdom.; Department of Immunology and Inflammation, Imperial College, London, W12 0NN, United Kingdom.; LonDownS: London Down Syndrome Consortium., Fisher EMC; Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, WC1N 3BG, United Kingdom elizabeth.fisher@ucl.ac.uk f.wiseman@ucl.ac.uk.; LonDownS: London Down Syndrome Consortium., Wiseman FK; The UK Dementia Research Institute, University College London, London, WC1N 3BG, United Kingdom elizabeth.fisher@ucl.ac.uk f.wiseman@ucl.ac.uk.; LonDownS: London Down Syndrome Consortium.

Publikováno v: The Journal of neuroscience : the official journal of the Society for Neuroscience [J Neurosci] 2022 Aug 17; Vol. 42 (33), pp. 6453-6468. Date of Electronic Publication: 2022 Jul 14.